iBio Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

Earnings (Loss) Per Common Share (Tables)

9 Months Ended

Mar. 31, 2022

Earnings (Loss) Per Common Share [Abstract]

Schedule of Earnings (loss) Per Share, Basic and Diluted


		Three Months Ended						Nine Months Ended
		March 31,						March 31,
		2022			2021			2022			2021
Basic and diluted numerator:

Net loss attributable to iBio, Inc.		$	(12,390)		$	(7,661)		$	(33,249)		$	(23,323)
Preferred stock dividends – iBio CMO Preferred Tracking Stock			—			(64)			(88)			(195)
Net loss available to iBio, Inc. stockholders		$	(12,390)		$	(7,725)		$	(33,337)		$	(23,518)

Basic and diluted denominator:

Weighted-average common shares outstanding			218,096			215,539			217,986			188,493

Per share amount		$	(0.06)		$	(0.04)		$	(0.15)		$	(0.12)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share


		March 31,
		2022		2021

		(in thousands)
Stock options		15,624		5,083
Restricted stock units		548		644
Warrant issued under the Transaction		1,290		—
Shares excluded from the calculation of diluted loss per share		17,462		5,727